1737 related articles for article (PubMed ID: 22972134)
21. Ten years of tiotropium: clinical impact and patient perspectives.
Yohannes AM; Connolly MJ; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2013; 8():117-25. PubMed ID: 23515335
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
Cope S; Zhang J; Williams J; Jansen JP
BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
[TBL] [Abstract][Full Text] [Related]
23. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
24. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2013 May; (5):CD007891. PubMed ID: 23728670
[TBL] [Abstract][Full Text] [Related]
25. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
Appleton S; Jones T; Poole P; Pilotto L; Adams R; Lasserson TJ; Smith B; Muhammad J
Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006101. PubMed ID: 16856113
[TBL] [Abstract][Full Text] [Related]
26. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
27. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
Kew KM; Seniukovich A
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010115. PubMed ID: 24615270
[TBL] [Abstract][Full Text] [Related]
28. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.
Cates CJ; Wieland LS; Oleszczuk M; Kew KM
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD010314. PubMed ID: 24504983
[TBL] [Abstract][Full Text] [Related]
29. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.
Fukuda N; Horita N; Kaneko A; Goto A; Kaneko T; Ota E; Kew KM
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD012066. PubMed ID: 37276335
[TBL] [Abstract][Full Text] [Related]
30. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.
Ducharme FM; Ni Chroinin M; Greenstone I; Lasserson TJ
Cochrane Database Syst Rev; 2010 May; (5):CD005535. PubMed ID: 20464739
[TBL] [Abstract][Full Text] [Related]
31. Beclometasone for chronic obstructive pulmonary disease.
De Coster DA; Jones M; Thakrar N
Cochrane Database Syst Rev; 2013 Oct; (10):CD009769. PubMed ID: 24105424
[TBL] [Abstract][Full Text] [Related]
32. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.
Geake JB; Dabscheck EJ; Wood-Baker R; Cates CJ
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010139. PubMed ID: 25575340
[TBL] [Abstract][Full Text] [Related]
33. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
34. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2010 May; (5):CD007891. PubMed ID: 20464758
[TBL] [Abstract][Full Text] [Related]
35. Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial.
Wechsler ME; Yawn BP; Fuhlbrigge AL; Pace WD; Pencina MJ; Doros G; Kazani S; Raby BA; Lanzillotti J; Madison S; Israel E;
JAMA; 2015 Oct; 314(16):1720-30. PubMed ID: 26505596
[TBL] [Abstract][Full Text] [Related]
36. Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.
Nannini LJ; Poole P; Milan SJ; Holmes R; Normansell R
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD003794. PubMed ID: 24214176
[TBL] [Abstract][Full Text] [Related]
37. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
38. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
39. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
[TBL] [Abstract][Full Text] [Related]
40. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
